Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagerman, Randi, Jacquemont, Sebastien, Berry-Kravis, Elizabeth, Des Portes, Vincent, Stanfield, Andrew, Koumaras, Barbara, Rosenkranz, Gerd, Murgia, Alessandra, Wolf, Christian, Apostol, George, von Raison, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242849/
https://www.ncbi.nlm.nih.gov/pubmed/30451888
http://dx.doi.org/10.1038/s41598-018-34978-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242849/
https://www.ncbi.nlm.nih.gov/pubmed/30451888
http://dx.doi.org/10.1038/s41598-018-34978-4

Ejemplares similares